HealiusASX:HLS +1.39%53 EBITDA Margin % is 11.48% as of Dec. 2025, which is 9% above its 10-year median of 10.52. GuruFocus rates ASX:HLS with a GF Score™ of 53/100 and a GF Value™ of A$1.01 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Healius ranks worse than 71.08% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Healius's EBITDA for the
six
months ended in Dec. 2025 was A$79 Mil. Healius's Revenue for the
six
months ended in Dec. 2025 was A$688 Mil. Therefore, Healius's EBITDA margin for the quarter that ended in Dec. 2025 was 11.48%.
Healius (ASX:HLS) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Healius EBITDA Margin % Related Terms
Healius EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Healius's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:HLS vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Healius's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Healius EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Healius's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Healius's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Healius (ASX:HLS) has a EBITDA Margin % of 11.48% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Healius and its competitors. This is near median its historical median of 10.52. According to the industry distribution chart, Healius ranks #145 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 71.1%.
Is Healius' EBITDA Margin % too high?
Healius' current EBITDA Margin % of 11.48% is near median its 10-year median of 10.52. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.20. Healius' value of 11.48% is 120.8% above this industry median. Based on the distribution chart, Healius ranks #145 out of 204 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Healius has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Healius' EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Healius ranks #145 out of 204 companies for EBITDA Margin %. This places Healius in the lower half of its industry. The industry median EBITDA Margin % is 5.20. Healius' value of 11.48% is 120.8% above this benchmark. While the company's 10-year median is 10.52 vs. the industry median of 5.20, Healius has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.20, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Healius's current EBITDA Margin % of 11.48% is 120.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Healius and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Healius's current EBITDA Margin % is 11.48%, which is near median its own 10-year median of 10.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Healius stock overvalued right now?
Based on GuruFocus' analysis, Healius (ASX:HLS) is currently considered Possible Value Trap. The stock's GF Value™ is A$1.01, compared to a current price of A$0.37 — trading 63.9% below its estimated fair value. The current EBITDA Margin % is 11.48%, which is near median its 10-year median of 10.52 and 120.8% above the Medical Diagnostics & Research industry median of 5.20. Healius' overall GF Score™ is 53/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Healius (ASX:HLS), the current EBITDA Margin % is 11.48% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Healius (ASX:HLS) Overvalued in 2026?
Based on GuruFocus' analysis, Healius stock appears to be undervalued.
The current stock price of A$0.37 is trading 63.9% below its estimated GF Value™ of A$1.01.
GuruFocus considers Healius to be Possible Value Trap.
Key valuation signals for ASX:HLS:
EBITDA Margin %: 11.48% (near median its 10-year median of 10.52)
GF Value™: A$1.01 vs. price of A$0.37 (63.9% below fair value)
Industry Position: 120.8% above the Medical Diagnostics & Research median (#145 of 204)
No single metric tells the full story. See the ASX:HLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Healius is Australia's second-largest pathology provider. Pathology revenue is almost entirely earned via the public health Medicare system and makes up the majority of Healius' group revenue. A small portion comes from its clinical testing business, Agilex.
53GF Score
Get the complete analysis for ASX:HLS
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:HLS has been successfully added to your 
